Impact of US Tariffs on Emerging Biopharma – Whitepaper Report

*This whitepaper report is available to download at no cost for registered users only. Once your account is created, you may add the report to your cart (any license level) and complete a zero-dollar order to access the downloadable PDF.

Tariffs. Uncertainty. Elongated timelines. Drug shortages. Stalled innovation. Higher costs.

There are not too many industries that thrive on uncertainty and the pharmaceutical industry is certainly not one of them. The biopharma industry is so dependent on a worldwide supply chain, regulatory structure, and pricing environment that even minor disruptions can have massive trickle-down effects. Senior executives can deal with one-time shocks that are of known impact, but the uncertainly of the US-driven tariff environment has left these executives struggling with multiple scenarios. On average, senior executives at emerging biopharma companies are spending ~13% of their valuable time strategizing about potential tariff impacts. According to our respondents, the initial impacts are centered on raw material access/pricing and manufacturing location uncertainty. Other than the obvious pricing impact, respondents identified a myriad of other potential impacts that tariffs, or even the potential of tariffs, could have on their company and the industry.

Our goal with this whitepaper report was not to solve any particular problem, but simply to shed light on the potential impacts of an uncertain tariff environment on the emerging biopharma industry, their service providers (CDMO, CRO, labs, clinical technology), VC/PE companies, principal investigators/sites, and patients.

Please enjoy, and we encourage you to share this complimentary resource with anyone in our industry.

Respondent profile:

• All respondents work at companies with less than $499M in annual R&D expenditure

• Companies have an average of 2.5 compounds in development

• Respondents have, on average, 22 years of industry experience

• 66% of respondents hold C-suite/President roles with the remaining 34% holding VP positions